In a significant announcement at the 2025 ASCO Annual Meeting, OnCusp Therapeutics unveiled the Phase 1a results of their groundbreaking drug, CUSP06. This CDH6-Directed Antibody-Drug Conjugate (ADC) has shown encouraging signs of efficacy in the treatment of platinum-refractory/resistant ovarian cancer and other advanced solid tumors. This revelation signals a potential paradigm shift in the ongoing […]
